Afficher la notice abrégée

Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa

dc.rights.licenseopenen_US
dc.contributor.authorKOLOU, Malewe
dc.contributor.authorPODA, Armel
dc.contributor.authorDIALLO, Zelica
dc.contributor.authorKONOU, Esther
dc.contributor.authorDOKPOMIWA, Tatiana
dc.contributor.authorZOUNGRANA, Jacques
dc.contributor.authorSALOU, Mounerou
dc.contributor.authorMBA-TCHOUNGA, Lionèle
dc.contributor.authorBIGOT, André
dc.contributor.authorOUEDRAOGO, Abdoul-Salam
dc.contributor.authorBOUYOUT-AKOUTET, Marielle
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorEKOUEVI, Didier Koumavi
dc.contributor.authorEHOLIE, Serge Paul
dc.date.accessioned2022-06-16T13:59:03Z
dc.date.available2022-06-16T13:59:03Z
dc.date.issued2021-07-22
dc.identifier.issn1471-2172en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/140246
dc.description.abstractEnBackground: The presence of the human leukocyte antigen HLA-B*57:01 is associated with the development of a hypersensitivity reaction to abacavir (ABC). Limited data exist on HLA-B*57:01 prevalence in individuals with HIV-1 in Africa. This study aimed to estimate HLA-B*57:01 prevalence in individuals with HIV-1 in West and Central Africa. Methods: A cross-sectional study was conducted in four countries in West and central Africa (Burkina-Faso, Côte d'Ivoire, Gabon, and Togo) from January 2016 to February 2020 to determine the status of HLA-B*57:01 in adults with HIV-1. The presence of HLA-B*57:01 was determined by using Single Specific Primer-Polymerase Chain Reaction (SSP-PCR) in blood samples. Prevalence rates were stratified based on country. Results: A total of 4016 (69.8% women) individuals with HIV were enrolled. Their median age was 45, and the interquartile range was 38-52. We included 500 (12.4%) patients in Burkina-Faso, 1453 (36.2%) in Côte d'Ivoire, 951 (23.7%) in Gabon, and 1112 (27.7%) in Togo. The overall HLA-B*57:01 prevalence was 0.1% [95% CI: 0.0-0.2%]. The prevalence of HLA-B*57:01 was similar according to the four countries. Only one case was reported in each country except Togo, with no cases. Conclusions: HLA-B*57:01 prevalence is low in individuals with HIV in West and central Africa, and there is no difference among countries. This study does not confirm the utility of HLA-B*57:01 allele testing for abacavir use in this region.
dc.language.isoENen_US
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.enAbacavir
dc.subject.enAnd Central Africa
dc.subject.enAntiretroviral
dc.subject.enHIV infection
dc.subject.enHLA-B*57:01
dc.subject.enPrevalence
dc.subject.enWest
dc.title.enPrevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa
dc.typeArticle de revueen_US
dc.identifier.doi10.1186/s12865-021-00427-7en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34294032en_US
bordeaux.journalBMC Immunologyen_US
bordeaux.page48en_US
bordeaux.volume22en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamMORPH3Eusen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=BMC%20Immunology&rft.date=2021-07-22&rft.volume=22&rft.issue=1&rft.spage=48&rft.epage=48&rft.eissn=1471-2172&rft.issn=1471-2172&rft.au=KOLOU,%20Malewe&PODA,%20Armel&DIALLO,%20Zelica&KONOU,%20Esther&DOKPOMIWA,%20Tatiana&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_BMCI_2021_Kolou.pdf
Taille:
666.0Ko
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée